Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enlivex ( (ENLV) ) just unveiled an announcement.
On April 21, 2026, Enlivex announced it received Clinical Trial Application approval from the Danish Medicines Agency to conduct a Phase 2b trial of Allocetra in patients with moderate-to-severe age-related primary knee osteoarthritis. This second regulatory green light follows recent U.S. FDA clearance, enabling enrollment in a global, multicenter, randomized, double-blind, placebo-controlled study across the United States, Denmark, and Poland.
The trial is statistically powered to assess Allocetra’s impact on pain, physical function, and quality of life at three and six months after intra-articular injection, positioning Enlivex to generate robust data in a disease that lacks approved disease‑modifying therapies. By expanding its osteoarthritis program into Europe, Enlivex strengthens its international clinical footprint and advances its strategy to address a large and growing aging population with limited treatment options.
The most recent analyst rating on (ENLV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is primarily constrained by weak financial performance—minimal revenue, ongoing operating losses, and continued cash burn—despite low leverage. Technicals also weigh on the rating as the stock trades below major moving averages with negative MACD. Valuation appears optically cheap due to the very low P/E, but that support is limited given questions about the sustainability of the reported earnings.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd., listed on Nasdaq as ENLV, is a “quality longevity” company developing Allocetra, a clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. The company also runs a prediction markets treasury strategy built around the Rain protocol on Arbitrum, combining biotech drug development with exposure to decentralized prediction markets.
Average Trading Volume: 568,395
Technical Sentiment Signal: Strong Sell
Current Market Cap: $194.7M
See more data about ENLV stock on TipRanks’ Stock Analysis page.